C07K 16/4208
Against an idiotypic determinant on ig
Official title: {against an idiotypic determinant on Ig}
C07K16/4208 (Against an idiotypic determinant on ig) appears on 512 US grants and 552 published applications in this corpus.
Search patents in C07K- Granted patents
- 512
- Published applications
- 552
- Assignees
- 340
- Inventors
- 1,264
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 4 | 0 |
| 1988 | 2 | 0 |
| 1989 | 7 | 0 |
| 1990 | 3 | 0 |
| 1991 | 5 | 0 |
| 1992 | 11 | 0 |
| 1993 | 15 | 0 |
| 1994 | 12 | 0 |
| 1995 | 14 | 0 |
| 1996 | 16 | 0 |
| 1997 | 21 | 0 |
| 1998 | 25 | 0 |
| 1999 | 29 | 0 |
| 2000 | 18 | 0 |
| 2001 | 24 | 5 |
| 2002 | 18 | 23 |
| 2003 | 11 | 23 |
| 2004 | 9 | 15 |
| 2005 | 14 | 24 |
| 2006 | 6 | 20 |
| 2007 | 9 | 16 |
| 2008 | 10 | 22 |
| 2009 | 12 | 22 |
| 2010 | 10 | 21 |
| 2011 | 10 | 13 |
| 2012 | 12 | 17 |
| 2013 | 16 | 12 |
| 2014 | 7 | 24 |
| 2015 | 10 | 17 |
| 2016 | 12 | 31 |
| 2017 | 24 | 26 |
| 2018 | 13 | 18 |
| 2019 | 11 | 19 |
| 2020 | 13 | 25 |
| 2021 | 11 | 26 |
| 2022 | 12 | 24 |
| 2023 | 9 | 28 |
| 2024 | 14 | 27 |
| 2025 | 15 | 35 |
| 2026 | 15 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Anti-idiotype antibody molecules and uses thereof25 Aug 2026US 12,715,934 B2Otsuka Pharmaceutical Co., Ltd.
- Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof11 Aug 2026US 12,703,762 B2Novartis AG
- Anti-vedolizumab antibodies and uses thereof28 Jul 2026US 12,693,298 B1Takeda Pharmaceutical Company Limited
- Anti-idiotypic antibodies to BCMA-targeted binding domains and related compositions and methods21 Jul 2026US 12,686,728 B2Juno Therapeutics, Inc.
- Alkali-tolerant affinity chromatography ligands14 Jul 2026US 12,679,873 B2Guangzhou Binding Technologies Co., Limited
- Vh4-34 antigen-binding molecules17 Sep 2026US 2026/0274993 A1Hummingbird Bioscience Pte. Ltd.
- Compositions and methods for improving tumor penetration of tumor specific antibodies10 Sep 2026US 2026/0265413 A1The Research Foundation for The State University of New York
- System and method for analyzing antibody co-formulations6 Aug 2026US 2026/0227390 A1Amgen Inc.
- Lysosome-Mediated Degradation of Extracellular Proteins16 Jul 2026US 2026/0199495 A1Washington University
- Humanized anti-acth antibodies and use thereof9 Jul 2026US 2026/0193344 A1H. Lundbeck A.S.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Production of chimeric antibodies - a combinatorial approach1,367US 5,565,332 ACambridge Antibody Technology Limited · 1996